Brief: Ocugen Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
16/01/2025 12:36
Jan 16 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
CLINICAL
TRIAL OF OCU200—A NOVEL INTEGRIN-TARGETING BIOLOGIC FOR DIABETIC
MACULAR EDEMA
* OCUGEN INC - TO PURSUE APPROVAL FOR OCU200 AS FIRST-LINE
THERAPY
FOR DME, DR, AND WET AMD
Source text: ID:nGNXbbj0H
Further company coverage: OCGN.O
((Reuters.Briefs@thomsonreuters.com;))